MAP2K7 and carcinoma: To further elucidate the inhibitory potential for MEK1, which regulates tumor cell proliferation, we tested BKI-1708 in a cellular proliferation assay in 4 carcinoma cell lines (A-375, Hs294T, MEWO, and Colo678) against a clinically approved MEK inhibitor, Trametinib [75,76].